^
ITM2A overexpression
Cervical Cancer
cisplatin
Sensitive: D – Preclinical
Bioengineered - 1 day
PTPRT mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Med - 4 days
PTPRT mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Med - 4 days
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 5 days
PD-L1 expression
NSCLC
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
ESMO-IO 2021 - 6 days
TERT mutation
Solid Tumor
Immunotherapy
Sensitive: C2 – Inclusion Criteria
ESMO-IO 2021 - 6 days
MSI-H/dMMR
Melanoma
ipilimumab biosimilar (CS1002) + CS1003
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
EGFR L858R
NSCLC
tislelizumab
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
EGFR exon 19 deletion
NSCLC
tislelizumab
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
MSI-H/dMMR
HCC
ipilimumab biosimilar (CS1002) + CS1003
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
BRAF mutation
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
STK11 mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
ESMO-IO 2021 - 6 days
TP53 mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
ESMO-IO 2021 - 6 days
NOTCH3 mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
PD-L1 expression
Neuroendocrine Tumor
toripalimab + surufatinib
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
PD-L1 expression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
PD-L1 expression
Gastric Cancer
toripalimab + surufatinib
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
PD-L1 overexpression
NSCLC
APL-502
Resistant: C3 – Early Trials
ESMO-IO 2021 - 6 days
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 1 week
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 1 week
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 week
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
Chugai Press Release - 1 week
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 week
BRCA2 mutation
Breast Cancer
ABT-888
Sensitive: B - Late Trials
Ann Oncol - 1 week
BRCA1 mutation
Breast Cancer
ABT-888
Sensitive: B - Late Trials
Ann Oncol - 1 week
HR negative
HER2 Positive Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
J Chemother - 1 week
ALK mutation
NSCLC
crizotinib + alectinib
Sensitive: C3 – Early Trials
Thorac Cancer - 1 week
HER-2 positive
CRC
HER2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
BioSpace - 2 weeks
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Gilead Press Release - 2 weeks
No biomarker
GIST
ripretinib
Sensitive: A1 - Approval
Deciphera Pharmaceuticals Press Release - 2 weeks
No biomarker
RCC
pembrolizumab
Sensitive: A1 - Approval
FDA - 2 weeks
No biomarker
Melanoma
BNT111
Sensitive: A1 - Approval
BioNTech Press Release - 2 weeks
PD-L1 expression
NSCLC
MT-6402
Sensitive: B - Late Trials
Molecular Templates Press Release - 2 weeks
No biomarker
CRC
arfolitixorin
Sensitive: B - Late Trials
Isofol Medical Press Release - 2 weeks
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: B - Late Trials
Ann Oncol - 2 weeks
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
Roche Press Release - 2 weeks
miR-142 overexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 2 weeks
miR-25 underexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 2 weeks
HER-2 negative
Gastric Adenocarcinoma
cisplatin + paclitaxel + capecitabine
Sensitive: C3 – Early Trials
Asia Pac J Clin Oncol - 2 weeks
HER-2 D769Y
LUAD
afatinib + anlotinib
Sensitive: C4 – Case Studies
World J Surg Oncol - 2 weeks
EGFR E709_T710delinsD
NSCLC
afatinib
Sensitive: C4 – Case Studies
J Med Case Rep - 2 weeks
H3.3K27M
Glioma
anlotinib
Sensitive: C4 – Case Studies
Acta Neurochir (Wien) - 2 weeks
HER-2 amplification
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
Nat Med - 3 weeks
KRAS A146 + TMB-H
CRC
bevacizumab
Sensitive: B - Late Trials
JCO Precis Oncol - 3 weeks
HR positive
HER2 Negative Breast Cancer
paclitaxel + cyclophosphamide oral + epirubicin
Sensitive: B - Late Trials
Eur J Cancer - 3 weeks
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
Amgen Press Release - 3 weeks
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks
HER-2 negative
HER2 Negative Breast Cancer
LY2780301
Sensitive: C2 – Inclusion Criteria
Eur J Cancer - 3 weeks
TMB-H
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
SLC29A1 overexpression
Pancreatic Cancer
gemcitabine
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
TP53 mutation
Ovarian Cancer
modafinil
Sensitive: C3 – Early Trials
Cancer Gene Ther - 3 weeks
ACTA2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
Clin Cancer Res - 3 weeks
TP53 mutation
Ovarian Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Gene Ther - 3 weeks
TMB-H
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
EGFR L747_T751delinsP
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: C3 – Early Trials
Thorac Cancer - 3 weeks
CDA underexpression + SLC29A1 underexpression
Pancreatic Cancer
5-fluorouracil
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
CDA underexpression + SLC29A1 overexpression
Pancreatic Cancer
gemcitabine
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
CDA underexpression
Pancreatic Cancer
gemcitabine
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
CDA underexpression
Pancreatic Cancer
5-fluorouracil
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
EZH2 rs201135441C>T
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
J Genet - 3 weeks
PIK3CA Q75E
SCCHN
alpelisib
Sensitive: C4 – Case Studies
J Clin Invest - 3 weeks
EGFR L861R
Lung Cancer
bevacizumab + afatinib
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 3 weeks
PD-L1 expression + EGFR mutation
NSCLC
pembrolizumab
Sensitive: C4 – Case Studies
J Oncol Pharm Pract - 3 weeks
miR-200b underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 3 weeks
miR-199b overexpression +miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 3 weeks
miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 3 weeks
miR-199b overexpression
Gastric Cancer
5-fluorouracil
Sensitive: D – Preclinical
DNA Cell Biol - 3 weeks
miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 3 weeks
miR-200b underexpression + miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 3 weeks
MET positive
Gastric Cancer
c-MET-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
STK11 mutation
NSCLC
BGB324
Sensitive: B - Late Trials
BerGenBio Press Release - 4 weeks
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 4 weeks
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
Sci Rep - 1 week
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
neratinib
Sensitive: A1 - Approval
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
Invest New Drugs - 2 weeks
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
Clin Cancer Res - 3 weeks
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Curr Probl Cancer - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
SABCS 2021 - 2 weeks
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
SCCHN
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
ESMO.org - 1 week
BRCA1 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
No biomarker
SCCHN
TPF
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
N Z Med J - 2 weeks
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval